MYCN is a well-known oncogene that is overexpressed in various malignant tumors, including neuroblastoma, rhabdomyosarcoma, medulloblastoma, and small-cell lung cancer [36,37,38,39]. This evidence concerns the gene MYCN and medulloblastoma.